Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > EU approves first I/O combination

<< Previous

Bullboard Posts

Next >>

Comment by itntdfon Jan 16, 2024 6:52pm

186 Views

Post# 35830205

RE:RE:RE:RE:EU approves first I/O combination

pela is not a standalone (yet) but it has been shown, when used first in a combo treatment, to enhance some of those other combo drugs.

so it would seem that would be attractive to the likes of roche, pfizer, merck etc.

can't have a p&b sandwich without both ingredients. seems that is what oncy is attempting to sell, but the sale would certainly be enhanced with some type of marketing approval associated with one of its fast-tracked indications.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario